AstraZeneca halts development of RA drug candidate fostamatinib

06/5/2013 | Reuters

AstraZeneca said it is stopping development of fostamatinib, a rheumatoid-arthritis-drug candidate licensed from Rigel Pharmaceuticals, after obtaining disappointing results from late-stage trials. AstraZeneca plans to return fostamatinib's rights to Rigel. Late-stage data failed to measure up to the promising results seen earlier in development, said Briggs Morrison, AstraZeneca's global head of medicines development.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT